Gainers
- Conformis CFMS shares moved upwards by 13.2% to $0.29 during Monday's after-market session. The company's market cap stands at $53.5 million.
- OKYO Pharma OKYO stock rose 13.08% to $2.68. Trading volume for this security closed at 111.8K, accounting for 101.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $58.3 million.
- Aytu BioPharma AYTU shares rose 11.96% to $0.57. The market value of their outstanding shares is at $21.9 million.
- Cabaletta Bio CABA stock moved upwards by 11.3% to $1.28. The market value of their outstanding shares is at $37.0 million.
- AN2 Therapeutics ANTX stock rose 10.64% to $8.42. The company's market cap stands at $163.3 million.
- AdaptHealth AHCO stock rose 9.86% to $24.5. The company's market cap stands at $3.2 billion.
Losers
- Enhabit EHAB stock fell 20.0% to $14.38 during Monday's after-market session. The market value of their outstanding shares is at $717.5 million. As per the press release, Q2 earnings came out today.
- Hyperfine HYPR shares declined by 6.21% to $1.21. The market value of their outstanding shares is at $85.1 million.
- Stealth BioTherapeutics MITO stock fell 5.35% to $0.27. This security traded at a volume of 1.0 million shares come close, making up 41.6% of its average volume over the last 100 days. The company's market cap stands at $20.1 million.
- TransMedics Group TMDX shares declined by 5.01% to $39.5. The company's market cap stands at $1.1 billion. As per the news, the Q2 earnings report came out today.
- Dermata Therapeutics DRMA stock declined by 5.0% to $0.55. The company's market cap stands at $5.0 million.
- Macrogenics MGNX stock declined by 4.81% to $2.97. The market value of their outstanding shares is at $182.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in